Anthropic launches AI drug discovery program, joining tech giants in healthcare

Anthropic, the AI company best known for building Claude, is making a deliberate push into the pharmaceutical world. The company launched its AI for Science program on May 5, 2025, offering free API credits to researchers working on drug discovery, genetics, and biology projects.

What the program actually does

The AI for Science program is designed to give qualified researchers access to Anthropic’s models at no cost. The research needs to focus on areas with significant potential impact, specifically biology, life sciences, genetic data analysis, and drug discovery for major global diseases.

The initiative is closely tied to CEO Dario Amodei’s publicly stated vision of using AI for broad societal benefit. The scope isn’t limited to one narrow application. Researchers can use the credits to work on understanding complex biological systems, analyzing genetic information, or accelerating the traditionally glacial process of identifying drug candidates.

From chatbots to clinical research

Anthropic followed up with the launch of Claude for Life Sciences in October 2025, a specialized version of its model built specifically for biomedical applications. That product integrates with tools that researchers actually use daily: PubMed for scientific literature, Benchling for lab experiment management, and ClinicalTrials.gov for tracking ongoing clinical studies.

The company’s commitment to this space became even more concrete in April 2026 with the acquisition of Coefficient Bio for approximately $400 million. Coefficient Bio brought AI-driven drug research and development expertise, giving Anthropic in-house capabilities rather than relying entirely on external researchers to validate its technology.

The competitive landscape is getting crowded

Anthropic isn’t operating in a vacuum here. Google DeepMind’s AlphaFold has already demonstrated that AI can solve problems in protein structure prediction that stumped biologists for decades. Microsoft has invested heavily in biomedical AI through partnerships and internal research.

Early results from Anthropic’s initiatives reportedly showed a 10x acceleration in certain drug design processes, and the company has pointed to successful candidate generation for protein targets. For Anthropic specifically, the healthcare push diversifies revenue beyond the consumer AI market, and positions the company in a sector where pharmaceutical companies routinely spend billions on R&D.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.